Daina Graybosch
Stock Analyst at Leerink Partners
(0.09)
# 4,687
Out of 4,994 analysts
499
Total ratings
39.1%
Success rate
-7.7%
Average return
Main Sectors:
Stocks Rated by Daina Graybosch
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MRK Merck & Co. | Rated: Buy | $114 → $161 | $150.91 | +6.69% | 78 | Sep 10, 2026 | |
| IPHA Innate Pharma | Upgraded: Buy | $2 → $4 | $1.80 | +122.22% | 33 | Aug 11, 2026 | |
| REPL Replimune Group | Upgraded: Buy | $17 | $13.47 | +26.21% | 2 | Aug 3, 2026 | |
| GILD Gilead Sciences | Downgraded: Hold | $129 → $127 | $152.67 | -16.81% | 29 | Jul 20, 2026 | |
| CGEN Compugen | Reiterated: Buy | $13 → $5 | $2.49 | +100.80% | 28 | May 21, 2026 | |
| RCUS Arcus Biosciences | Reiterated: Buy | $49 → $47 | $26.87 | +74.92% | 25 | Apr 20, 2026 | |
| BNTX BioNTech SE | Downgraded: Hold | $107 → $113 | $100.87 | +12.03% | 67 | Feb 2, 2026 | |
| IPSC Century Therapeutics | Downgraded: Hold | $7 → $2 | $1.89 | +5.82% | 26 | Nov 17, 2025 | |
| SMMT Summit Therapeutics | Reiterated: Sell | n/a | $17.12 | - | 7 | Oct 22, 2025 | |
| NBP NovaBridge Biosciences | Initiated Coverage: Buy | $9 | $1.59 | +466.04% | 1 | Oct 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $20 → $6 | $3.71 | n/a | 21 | Sep 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $12 → $7 | $2.58 | n/a | 37 | Sep 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $12 → $10 | $0.982 | n/a | 20 | Sep 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $28 | $9.04 | n/a | 2 | Aug 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $7 | $3.23 | n/a | 2 | Aug 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $8 | $2.95 | n/a | 20 | Aug 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $5 → $0.39 | $0.0001 | n/a | 32 | May 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $6 | $4.26 | n/a | 19 | Aug 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $69.66 | n/a | 1 | Dec 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $1.5 | $60.97 | n/a | 26 | Sep 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $5.36 | n/a | 1 | Jun 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $5 | $0.0001 | n/a | 10 | Apr 27, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $25 → $1.8 | $4.48 | n/a | 8 | Apr 1, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | CHF 35.00 | CHF 3.40 | n/a | 1 | Apr 6, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | €82.38 → €86.71 | €133.15 | n/a | 3 | Aug 25, 2020 |
Merck & Co.
Sep 10, 2026
Rated: Buy
Price Target: $114 → $161
Current: $150.91
Upside: +6.69%
Innate Pharma
Aug 11, 2026
Upgraded: Buy
Price Target: $2 → $4
Current: $1.80
Upside: +122.22%
Replimune Group
Aug 3, 2026
Upgraded: Buy
Price Target: $17
Current: $13.47
Upside: +26.21%
Gilead Sciences
Jul 20, 2026
Downgraded: Hold
Price Target: $129 → $127
Current: $152.67
Upside: -16.81%
Compugen
May 21, 2026
Reiterated: Buy
Price Target: $13 → $5
Current: $2.49
Upside: +100.80%
Arcus Biosciences
Apr 20, 2026
Reiterated: Buy
Price Target: $49 → $47
Current: $26.87
Upside: +74.92%
BioNTech SE
Feb 2, 2026
Downgraded: Hold
Price Target: $107 → $113
Current: $100.87
Upside: +12.03%
Century Therapeutics
Nov 17, 2025
Downgraded: Hold
Price Target: $7 → $2
Current: $1.89
Upside: +5.82%
Summit Therapeutics
Oct 22, 2025
Reiterated: Sell
Price Target: n/a
Current: $17.12
Upside: -
NovaBridge Biosciences
Oct 6, 2025
Initiated Coverage: Buy
Price Target: $9
Current: $1.59
Upside: +466.04%
Sep 4, 2025
Reiterated: Hold
Price Target: $20 → $6
Current: $3.71
Upside: n/a
Sep 4, 2025
Reiterated: Buy
Price Target: $12 → $7
Current: $2.58
Upside: n/a
Sep 4, 2025
Reiterated: Buy
Price Target: $12 → $10
Current: $0.982
Upside: n/a
Aug 15, 2025
Reiterated: Buy
Price Target: $28
Current: $9.04
Upside: n/a
Aug 13, 2025
Reiterated: Buy
Price Target: $7
Current: $3.23
Upside: n/a
Aug 13, 2025
Reiterated: Buy
Price Target: $8
Current: $2.95
Upside: n/a
May 14, 2025
Downgraded: Hold
Price Target: $5 → $0.39
Current: $0.0001
Upside: n/a
Aug 28, 2024
Reiterated: Hold
Price Target: $6
Current: $4.26
Upside: n/a
Dec 11, 2023
Reiterated: Buy
Price Target: n/a
Current: $69.66
Upside: n/a
Sep 15, 2023
Reiterated: Hold
Price Target: $1.5
Current: $60.97
Upside: n/a
Jun 5, 2023
Reiterated: Buy
Price Target: n/a
Current: $5.36
Upside: n/a
Apr 27, 2022
Reiterated: Buy
Price Target: $5
Current: $0.0001
Upside: n/a
Apr 1, 2022
Downgraded: Hold
Price Target: $25 → $1.8
Current: $4.48
Upside: n/a
Apr 6, 2021
Reiterated: Buy
Price Target: CHF 35.00
Current: CHF 3.40
Upside: n/a
Aug 25, 2020
Reiterated: Buy
Price Target: €82.38 → €86.71
Current: €133.15
Upside: n/a